Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Onivyde (nanoliposomal irinotecan)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ipsen, PharmaEngine, Servier, Takeda, Yakult Honsha

Drug class:

Topoisomerase I inhibitor

Related drugs:

‹

irinotecan liposomal (0)

topotecan episcleral (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline 5-fluorouracil + nanoliposomal irinotecan Sensitive : A2	5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline 5-fluorouracil + nanoliposomal irinotecan Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	nanoliposomal irinotecan Sensitive: B - Late Trials nanoliposomal irinotecan Sensitive : B	nanoliposomal irinotecan Sensitive: B - Late Trials nanoliposomal irinotecan Sensitive : B